Skip to main content


Showing posts from February 1, 2009

Transplants: Stem cells, faces, lungs ... such miracles for our time

The miracle of transplant medicine is an omnipresent feature of my life. Since the successful stem cell transplant that cured one of the most aggressive forms of non-Hodgkin's Lymphoma (mantle cell) in August 2007, reports of similar medical miracles through transplantation capture my attention. Two such stories are clipped below. These episodes are more than simple facts, but these accounts tell the abilities of protagonists to overcome insurmountable odds to regain, health, hope, and life.

She can eat pizza. And hamburgers. She can smell perfume, drink coffee from a cup, and purse her lips as if to blow a kiss. Except that one lip is hers, and the other is from a dead woman. She is the nation's first face transplant patient, and on Thursday night, she went home from a Cleveland hospital. "I'm happy about myself," she told her doctors. | @ltaLINK | @ltaSEARCH

First US face transplant patient leaves hospital
The Associated Press | 2.7.09 | Doctors say the woman …

Advances in the Treatment of Non-Hodgkin’s Lymphoma

New and Novel Agents for the Treatment of Non-Hodgkin's Lymphoma: A Report from the 2008 Meeting of the American Society of HematologyThe 2008 ASH meeting featured several reports of new agents that are showing promise in the treatment of Non-Hodgkin's Lymphoma (NHL).

Revlimid for Mantle Cell Lymphoma and Diffuse Large B-cell LymphomaRevlimid® (lenalidomide) is an orally administered derivative of thalidomide, a very active agent for the treatment of multiple myeloma. Revlimid also has anti-angiogeneic properties as well as numerous possible immune and biologic properties. Clinical trials have also documented activity for Revlimid in renal cell carcinoma, myelodysplastic syndromes, and CLL. Revlimid also has significant activity in patients with relapsed or refractory aggressive NHL, including mantle cell lymphoma. | @ltaLINK | @ltaSEARCH